Healthcare stocks haven't gotten a lot of love from investors in recent years. While the market has been strong and the S&P ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

European shares rose on Thursday as lower-than-expected U.S. inflation strengthened hopes for Federal Reserve interest rate ...

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...

Eli Lilly's oral pill helped maintain weight loss in patients switching from injectable versions of GLP-1 drugs, the company ...

Novo Nordisk (NVO) stock gains as the company files for FDA approval of CagriSema, its next-gen obesity drug which causes up ...

Novo Nordisk said on Thursday it filed a marketing application to the U.S. Food and Drug Administration for CagriSema, its once-weekly next-generation weight-loss drug.

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

U.S. President Donald ​Trump ⁠in July sent letters to 17 drugmakers urging them to slash prices. Pfizer and AstraZeneca first ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

European shares were muted on Thursday as investors adopted a largely cautious stance ahead of a series of central bank ...